Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery
Sanjiv J. Shah, MD*, ,
David D. Waters, MD*,*,
Philip Barter, MD ,
John J.P. Kastelein, MD, PhD ,
James Shepherd, MD||,
Nanette K. Wenger, MD¶,
David A. DeMicco, DPharm#,
Andrei Breazna, PhD# and
John C. LaRosa, MD**
* Division of Cardiology, San Francisco General Hospital, and the Department of Medicine, University of California, San Francisco, California
Division of Cardiology, Department of Medicine, Northwestern University, Chicago, Illinois
Heart Research Institute, Sydney, Australia
Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
|| University of Glasgow, Glasgow, United Kingdom
¶ Emory University School of Medicine, Atlanta, Georgia
# Pfizer Inc., New York, New York
** State University of New York Health Science Center, New York, New York.

View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Kaplan-Meier Curves for a Primary End-Point Event in Patients With and Without Prior CABG
Primary end points were cardiac death, myocardial infarction, resuscitated cardiac arrest, and stroke. CABG = coronary artery bypass graft surgery; CI = confidence interval; HR = hazard ratio.
|
|

View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Kaplan-Meier Curves for Coronary Revascularization Among Patients With Prior CABG
Revascularization was either repeat CABG or percutaneous coronary intervention, in the 80- and 10-mg atorvastatin groups among patients with prior CABG at baseline. Abbreviations as in Figure 1.
|
|
|